Clinical trials: Anthracyclines
Cancer, Breast Cancer
Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer
The purpose of this clinical research study is to learn if BMS-247550 added to the approved therapy of capecitabine (Xeloda) provides measurable clinical benefits over capecitabine alone in women with metastatic breast cancer.
- Trial name
- NCT00082433
- Testing
- Ixabepilone + Capecitabine, Capecitabine
- Where
- 186 sites in United States, Argentina and 27 more
- Volunteers
- 1,221 people
- Sponsor
- R-Pharm
Newly Diagnosed AML With FLT3 Activating Mutations
A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations
This pilot study is designed to evaluate the safety and tolerability of oral crenolanib besylate given sequentially during standard induction and consolidation chemotherapy in patients with newly diagnosed AML with FLT3…
- Trial name
- NCT02283177
- Testing
- crenolanib, cytarabine, daunorubicin
- Where
- 9 sites in United States
- Volunteers
- 44 people
- Sponsor
- Arog Pharmaceuticals, Inc.
Breast Cancer, Metastases
Trial of Vinflunine Versus Alkylating Agent in Metastatic Breast Cancer
In metastatic breast cancer (MBC) patients who have already received anthracyclines, taxanes, antimetabolites and vinca-alkaloids and have developed drug resistance to these drugs, therapeutic options are very limited.
- Trial name
- NCT01091168
- Testing
- vinflunine, Alkylating agent of physician choice registered in cancer
- Where
- 80 sites in Argentina, Austria and 12 more
- Volunteers
- 594 people
- Sponsor
- Pierre Fabre Medicament
CINV
Dose-finding Study of APD403 to Prevent Nausea and Vomiting After Chemotherapy
Comparison of efficacy of APD403 at preventing delayed sickness in patients who have received cancer chemotherapy
- Trial name
- NCT01857232
- Testing
- Ondansetron, Dexamethasone, Fosaprepitant
- Where
- Denmark
- Volunteers
- 342 people
- Sponsor
- Acacia Pharma Ltd
Metastases, Brain
Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer
This open label study was designed to evaluate Lapatinib effect on incidence of brain metastases in ErbB2 (HER2) positive metastatic breast cancer patients exposed to prior taxanes or anthracyclines.
- Trial name
- NCT00820222
- Testing
- capecitabine, lapatinib, trastuzumab
- Where
- 164 sites in United States, Belgium and 12 more
- Volunteers
- 540 people
- Sponsor
- Novartis Pharmaceuticals
Chemotherapy-induced Nausea and Vomiting
A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer
Multicenter, randomized, double-blind, double-dummy, parallel group, stratified study assessing the safety and describing the efficacy of a single dose of intravenous (IV) fosnetupitant/palonosetron (260 mg/0.25 mg) infusion…
- Trial name
- NCT03403712
- Testing
- fosnetupitant/ palonosetron, netupitant/palonosetron, dexamethasone
- Where
- 40 sites in United States, Georgia
- Volunteers
- 404 people
- Sponsor
- Helsinn Healthcare SA
Breast Cancer
Gemcitabine Combinations in Metastatic Breast Cancer (MBC), 1st Line
The gemcitabine-paclitaxel and gemcitabine-platinum combinations have shown promise in the treatments of MBC; however, the optimal dosing schedules for these combinations have not yet been determined.
- Trial name
- NCT00191854
- Testing
- gemcitabine, paclitaxel, carboplatin
- Where
- 18 sites in Brazil, China and 4 more
- Volunteers
- 147 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer
The purpose of this study is to compare Overall Survival (OS), Progression Free Survival (PFS), objective tumor response rate, duration of response, and safety in patients treated with E7389 versus the Treatment of Physician's…
- Trial name
- NCT00388726
- Testing
- E7389, Physician's Choice
- Where
- 137 sites in United States, Argentina and 15 more
- Volunteers
- 762 people
- Sponsor
- Eisai Inc.
Breast Cancer
Enzastaurin in Combination of Capecitabine to Treat Breast Cancer
The purpose of this study is to determine whether the combination of enzastaurin and capecitabine is more effective than the combination of placebo and capecitabine in treating participants with breast cancer who were previously…
- Trial name
- NCT00437294
- Testing
- enzastaurin, capecitabine
- Where
- 20 sites in Argentina, Australia and 3 more
- Volunteers
- 86 people
- Sponsor
- Eli Lilly and Company
Liposarcoma, Leiomyosarcoma
A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer
The purpose of this study is to test the safety and effectiveness of an investigational chemotherapy agent in patients with types of advanced cancer referred to as liposarcoma or leiomyosarcoma.
- Trial name
- NCT00060944
- Testing
- Yondelis, Dexamethasone
- Where
- 39 sites in United States, Australia and 6 more
- Volunteers
- 271 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Metastasis, Breast Cancer
A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine
This is an open-label, randomized, active comparator, multicenter, international Phase 3 study of NKTR-102 versus TPC in patients with metastatic breast cancer who have stable brain metastases and have been previously treated…
- Trial name
- ATTAIN (NCT02915744)
- Testing
- NKTR-102, Eribulin, Ixabepilone
- Where
- 56 sites in United States, Australia and 8 more
- Volunteers
- 178 people
- Sponsor
- Nektar Therapeutics
Breast Cancer
A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer
This single-arm open-label study assessed the safety, feasibility, and efficacy of trastuzumab emtansine (T-DM1) after the completion of anthracycline-based adjuvant/neoadjuvant chemotherapy in patients with early HER2-positive…
- Trial name
- NCT01196052
- Testing
- Trastuzumab emtansine
- Where
- 44 sites in United States, Belgium and 6 more
- Volunteers
- 153 people
- Sponsor
- Hoffmann-La Roche
Metastatic Breast Cancer
Efficacy Study of Gemcitabine-Paclitaxel to Treat Metastatic Breast Cancer
The purpose of this study is to determine the response rate to a gemcitabine-paclitaxel combination administered on a 3-weekly schedule in Chinese patients with unresectable, locally recurrent breast cancer or metastatic breast…
- Trial name
- NCT00316199
- Testing
- gemcitabine, paclitaxel
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Eli Lilly and Company
Metastatic Breast Cancer
E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes
The purpose of this study is to compare E7389 versus capecitabine in patients with locally advanced or metastatic breast cancer who are refractory to the most recent chemotherapy.
- Trial name
- NCT00337103
- Testing
- Eribulin Mesylate, Capecitabine
- Where
- 169 sites in United States, Argentina and 21 more
- Volunteers
- 1,276 people
- Sponsor
- Eisai Inc.
Breast Cancer
Trial of Vinflunine Plus Capecitabine in Advanced Breast Cancer
The increasing use of anthracyclines and taxanes in the adjuvant, neoadjuvant and first-line metastatic settings, led to a raise of patients presenting with metastatic breast cancer after treatment with these agents.
- Trial name
- NCT01095003
- Testing
- Vinflunine plus Capecitabine, Capecitabine
- Where
- 110 sites in Argentina, Belarus and 19 more
- Volunteers
- 770 people
- Sponsor
- Pierre Fabre Medicament
Breast Cancer
A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer
This two-arm, randomized, open-label, multicenter study will evaluate the efficacy and safety of trastuzumab emtansine in combination with pertuzumab versus trastuzumab in combination with pertuzumab and a taxane as adjuvant…
- Trial name
- NCT01966471
- Testing
- Trastuzumab Emtansine, Trastuzumab, Pertuzumab
- Where
- 295 sites in United States, Australia and 34 more
- Volunteers
- 1,846 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast Cancer
The primary purpose of this study is to help answer the following research questions: whether the chemotherapy combination therapy Pemetrexed-Carboplatin or Gemcitabine-Vinorelbine can help participants with advanced breast…
- Trial name
- NCT00325234
- Testing
- Pemetrexed, Carboplatin, Gemcitabine
- Where
- 22 sites in Germany, Italy and 3 more
- Volunteers
- 135 people
- Sponsor
- Eli Lilly and Company
Metastatic Breast Cancer
Gemcitabine Monotherapy for Metastatic Breast Cancer After Anthracycline and Taxane Regimen
To investigate efficacy, safety and PK of GEM monotherapy after prior chemotherapy with anthracycline and taxane regimen for patients with metastatic breast cancer
- Trial name
- NCT00191269
- Testing
- gemcitabine
- Where
- 13 sites in Japan
- Volunteers
- 68 people
- Sponsor
- Eli Lilly and Company
Metastatic Soft-tissue Sarcoma
A Study of NOX66 Plus Doxorubicin in Anthracycline-naïve, Adult Patients With Soft Tissue Sarcoma
This is a Phase I, open-label, dose-escalation and dose-expansion study of NOX66 given rectally, in cohorts of patients with metastatic soft tissue sarcoma (STS) who have not been exposed to anthracycline therapy, using a fixed…
- Trial name
- NCT05100628
- Testing
- NOX66, Doxorubicin
- Where
- 4 sites in United States
- Volunteers
- 9 people
- Sponsor
- Noxopharm Limited
Triple-negative Breast Cancer
A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer
This is a global Phase III, double-blind, randomized, placebo-controlled study designed to evaluate the efficacy and safety of neoadjuvant treatment with atezolizumab (anti-programmed death-ligand 1 [anti-PD-L1] antibody) and…
- Trial name
- IMpassion031 (NCT03197935)
- Testing
- Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody, Nab-paclitaxel, Doxorubicin
- Where
- 68 sites in United States, Australia and 11 more
- Volunteers
- 333 people
- Sponsor
- Hoffmann-La Roche